Cardiff Oncology, a clinical-stage biotech company focused on cancer therapies using PLK1 inhibition, announced its participation in the Jefferies Global Healthcare Conference from June 2 to 4, 2026. The company's CEO, Mani Mohindru, will present in a fireside chat on June 4, discussing their lead drug onvansertib, currently in Phase 2 trials for RAS-mutated metastatic colorectal cancer. This presentation highlights Cardiff's progress in developing treatments for hard-to-treat cancers and plans for advancing their clinical programs. Interested investors can access the live webcast and replay via the company's website.
Wescan Goldfields Inc. has closed the first tranche of its private placement, raising $2.24 million by issuing over 10 million units at $0.22 each. Each unit includes one common share and half a warrant to buy more shares at $0.35 within two years. T...
In recognition of National Homeownership Month, First Federal Savings Bank and the Independent Community Bankers of America (ICBA) are advising prospective homebuyers to work with local community banks for guidance. They emphasize steps like securing...
Verizon Communications announced a quarterly dividend of 70.75 cents per share, maintaining the same rate as the previous quarter. The dividend will be paid on August 3, 2026, to shareholders recorded by July 10, 2026. Verizon highlighted its 20 cons...
Guidewire Software reported better-than-expected Q3 results with adjusted earnings of 82 cents per share and revenue of $372.54 million, surpassing analyst estimates. Subscription and support revenue rose 35%, while license revenue slightly declined ...
SuperX AI Technology Limited will showcase its new 1.6T optical module and a range of AI data center infrastructure solutions at Interop Tokyo 2026. These include AI compute platforms, a modular AI factory, and an 800V DC power architecture designed ...
